Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA

被引：29

作者：

Marinaro, M

Riccomi, A

Rappuoli, R

Pizza, M

Fiorelli, V

Tripiciano, A

Cafaro, A

Ensoli, B

De Magistris, MT

机构：

[1] Ist Super Sanita, Lab Bacteriol & Med Mycol, I-00161 Rome, Italy

[2] Chiron Spa, I-53100 Siena, Italy

[3] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy

来源：

VACCINE | 2003年 / 21卷 / 25-26期

关键词：

mucosal vaccines; adjuvants; HIV-1 Tat protein;

D O I：

10.1016/S0264-410X(03)00295-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Human immunodeficiency virus (HIV)-1 Tat protein induces protection in non-human primates upon systemic vaccination. In view of the design of mucosal vaccines against HIV-1 we studied the immune response to native Tat (aa 1-86) in mice following intranasal delivery of the protein with two mucosal adjuvants, Escherichia coli heat-labile enterotoxin (LT) and LT-R72, a non-toxic mutant of LT. Immunization with Tat and the two adjuvants induced in BALB/c but not in C57BL/6 mice high and persistent levels of serum IgG and secretory IgA in vaginal and intestinal fluids. Mice sera neutralized Tat and recognized two epitopes mapping in the regions 1-20 and 46-60. Furthermore, their splenocytes proliferated and secreted IFN-gamma and IL-6 in response to Tat. Finally, CTLs were also elicited and they recognized an epitope localized within aa 11-40 of Tat. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：3972 / 3981

页数：10

共 56 条

[1] The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals [J].

Addo, MM ;

Altfeld, M ;

Rosenberg, ES ;

Eldridge, RL ;

Philips, MN ;

Habeeb, K ;

Khatri, A ;

Brander, C ;

Robbins, GK ;

Mazzara, GP ;

Goulder, PJR ;

Walker, BD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1781-1786

[2] Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].

Allen, TM ;

O'Connor, DH ;

Jing, PC ;

Dzuris, JL ;

Mothé, BR ;

Vogel, TU ;

Dunphy, E ;

Liebl, ME ;

Emerson, C ;

Wilson, N ;

Kunstman, KJ ;

Wang, XC ;

Allison, DB ;

Hughes, AL ;

Desrosiers, RC ;

Altman, JD ;

Wolinsky, SM ;

Sette, A ;

Watkins, DI .

NATURE, 2000, 407 (6802) :386-390

[3] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].

Baba, TW ;

Liska, V ;

Hofmann-Lehmann, R ;

Vlasak, J ;

Xu, WD ;

Ayehunie, S ;

Cavacini, LA ;

Posner, MR ;

Katinger, H ;

Stiegler, G ;

Bernacky, BJ ;

Rizvi, TA ;

Schmidt, R ;

Hill, LR ;

Keeling, ME ;

Lu, YC ;

Wright, JE ;

Chou, TC ;

Ruprecht, RM .

NATURE MEDICINE, 2000, 6 (02) :200-206

[4]

Barillari G, 1999, BLOOD, V94, P663

[5] Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type I highly exposed, persistently seronegative female sex workers in northern Thailand [J].

Beyrer, C ;

Artenstein, AW ;

Rugpao, S ;

Stephens, H ;

VanCott, TC ;

Robb, ML ;

Rinkaew, M ;

Birx, DL ;

Khamboonruang, C ;

Zimmerman, PA ;

Nelson, KE ;

Natpratan, C .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :59-67

[6] CHARACTERIZATION OF MURINE MONOCLONAL-ANTIBODIES TO THE TAT PROTEIN FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].

BRAKE, DA ;

GOUDSMIT, J ;

KRONE, WJA ;

SCHAMMEL, P ;

APPLEBY, N ;

MELOEN, RH ;

DEBOUCK, C .

JOURNAL OF VIROLOGY, 1990, 64 (02) :962-965

[7] In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [J].

Brodie, SJ ;

Lewinsohn, DA ;

Patterson, BK ;

Jiyamapa, D ;

Krieger, J ;

Corey, L ;

Greenberg, PD ;

Riddell, SR .

NATURE MEDICINE, 1999, 5 (01) :34-41

[8] Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].

Cafaro, A ;

Caputo, A ;

Fracasso, C ;

Maggiorella, MT ;

Goletti, D ;

Baroncelli, S ;

Pace, M ;

Sernicola, L ;

Koanga-Mogtomo, ML ;

Betti, M ;

Borsetti, A ;

Belli, R ;

Åkerblom, L ;

Corrias, F ;

Buttò, S ;

Heeney, J ;

Verani, P ;

Titti, F ;

Ensoli, B .

NATURE MEDICINE, 1999, 5 (06) :643-650

[9] Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) [J].

Cafaro, A ;

Titti, F ;

Fracasso, C ;

Maggiorella, MT ;

Baroncelli, S ;

Caputo, A ;

Goletti, D ;

Borsetti, A ;

Pace, M ;

Fanales-Belasio, E ;

Ridolfi, B ;

Negri, DRM ;

Sernicola, L ;

Belli, R ;

Corrias, F ;

Macchia, I ;

Leone, P ;

Michelini, Z ;

ten Haaft, P ;

Buttò, S ;

Verani, P ;

Ensoli, B .

VACCINE, 2001, 19 (20-22) :2862-2877

[10] SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine [J].

Cafaro, A ;

Caputo, A ;

Maggiorella, MT ;

Baroncelli, S ;

Fracasso, C ;

Pace, M ;

Borsetti, A ;

Sernicola, L ;

Negri, DRM ;

Ten Haaft, P ;

Betti, M ;

Michelini, Z ;

Macchia, I ;

Fanales-Belasio, E ;

Belli, R ;

Corrias, F ;

Buttò, S ;

Verani, P ;

Titti, F ;

Ensoli, B .

JOURNAL OF MEDICAL PRIMATOLOGY, 2000, 29 (3-4) :193-208

← 1 2 3 4 5 6 →